Skip to main content

Advertisement

Table 3 Clinical-pathological parameters of patients in the screening and validation cohort

From: Identification of the dopamine transporter SLC6A3 as a biomarker for patients with renal cell carcinoma

  microarray screening cohort PCR validation cohort tissue microarray cohort
  n = 15 (%) cancer n = 52 (%) normal n = 51 (%) n = 134 (%)
Sex
 male 10 (66.6) 35 (67.3) 35 (68.6) 85 (63.4)
 female 5 (33.3) 17 (32.7) 16 (31.4) 49 (36.6)
Age
 mean 61.2 62.5 62.0 62.3
 min-max 43-86 36-86 36-86 33-85
Pathological stage
 pT1 4 (26.7) 29 (55.8) n.a. 55 (41.0)
 pT2 2 (13.3) 5 (9.6) n.a. 30 (22.4)
 pT3 9 (60.0) 17 (32.7) n.a. 47 (35.1)
 pT4 0 (0) 1 (1.9) n.a. 2 (1.5)
lymph node metastasis 0 (0) 2 (3.8) n.a. 7 (5.2)
distant metastasis 1 (6.7) 7 (13.5) n.a. 17 (12.7)
Fuhrman Grading
 grade 1 2 (13.3) 4 (7.7) n.a. 40 (29.9)
 grade 2 11 (73.3) 40(76.9) n.a. 91 (67.9)
 grade 3 2 (13.3) 7 (13.5 %) n.a. 3 (2.2)
 grade 4 0 (0) 1 (1.9) n.a. 0
  1. n.a. not applicable